CUMBERLAND PHARMACEUTICALS INC (CPIX) Financial Statements — Income, Balance Sheet, Cash Flow

Overview Financials Chart Business Summary Filings Ownership Valuation

Financial Statements — CPIX

Balance Sheet

(in millions USD)

Metric	Q3 2025	Q2 2025	Q1 2025	Q3 2024	Q2 2024	Q1 2024	Q3 2023	Q2 2023	Q1 2023	Q3 2022	Q2 2022	Q1 2022	Q3 2021	Q2 2021	Q1 2021
Cash & Equivalents	15.20	16.09	11.01	17.46	17.34	18.55	18.51	18.25	16.39	19.54	18.22	17.27	25.84	25.67	24.92
Accounts Receivable	10.43	10.32	14.26	11.31	11.62	10.65	12.62	12.22	14.53	15.23	13.28	14.64	9.85	9.15	12.55
Inventory	2.93	3.22	5.45	4.51	4.30	4.33	8.67	10.93	10.18	10.65	9.42	9.88	10.26	10.10	10.01
Total Current Assets	29.94	31.21	32.79	35.24	35.58	36.21	41.77	43.67	43.81	49.16	43.75	45.34	47.22	46.68	49.38
Property, Plant & Equipment	0.29	0.30	0.24	0.31	0.34	0.37	0.38	0.38	0.35	0.49	0.46	0.41	0.49	0.49	0.53
Goodwill	0.91	0.91	0.91	0.91	0.91	0.91	0.91	0.91	0.91	1.93	1.93	1.93	0.88	0.88	0.88
Intangible Assets	15.01	15.99	12.79	19.42	20.46	21.52	27.12	28.27	29.39	29.05	32.98	34.48	24.92	25.89	27.02
Total Non-current Assets*	35.96	36.70	38.21	41.51	42.94	45.30	45.98	45.70	45.66	41.62	48.77	51.36	40.36	42.17	43.97
Total Assets	65.90	67.91	71.00	76.75	78.52	81.51	87.75	89.38	89.47	90.78	92.52	96.70	87.57	88.85	93.35
Accounts Payable	13.83	13.45	16.54	12.06	12.51	13.08	10.82	10.91	11.22	11.51	10.59	11.45	9.23	8.96	10.47
Total Current Liabilities	24.31	23.97	34.49	31.09	24.76	26.43	27.33	26.96	25.71	25.31	24.25	24.56	17.95	18.65	22.85
Total Non-current Liabilities*	15.79	16.26	15.20	21.19	27.73	27.89	24.77	25.58	27.71	26.98	29.06	31.35	22.98	22.40	23.62
Total Liabilities	40.10	40.23	49.69	52.28	52.49	54.32	52.10	52.54	53.42	52.29	53.31	55.90	40.92	41.04	46.47
Retained Earnings	(25.39)	(23.45)	(30.09)	(22.06)	(20.52)	(19.43)	(11.19)	(10.14)	(11.02)	(8.77)	(8.36)	(7.02)	(1.79)	(0.74)	(1.96)
Total Stockholder Equity	26.12	27.99	21.64	24.78	26.35	27.49	35.99	37.16	36.36	38.76	39.46	41.02	46.82	47.95	47.02

* Derived from reported values

Income Statement

(in millions USD) (except per-share rows)

Metric	Q4 2025	Q3 2025	Q2 2025	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022	Q2 2022	Q1 2022	Q4 2021	Q3 2021	Q2 2021	Q1 2021
Total Revenue	13.68	8.29	10.84	9.13	10.44	9.09	9.85	8.50	9.35	10.09	10.89	9.22	7.79	11.41	10.30	11.18	7.38	8.07	9.06	10.54
Cost of Revenue	2.24	0.99	2.01	1.93	1.98	1.32	1.71	1.58	1.53	1.77	1.52	1.25	2.65	2.22	2.03	2.21	3.33	1.33	1.74	2.42
Gross Profit	11.44	7.30	8.83	7.20	8.46	7.76	8.14	6.92	7.82	8.32	9.37	7.97	6.47	9.19	8.27	8.96	4.99	6.74	7.31	8.12
Research & Development	1.55	1.25	1.47	1.46	1.29	1.31	1.06	1.16	1.26	1.92	1.15	1.50	1.41	1.71	1.82	1.75	1.61	1.45	1.36	1.26
Selling, General & Admin	4.04	2.57	2.87	2.55	3.33	2.68	2.76	2.37	3.44	2.34	2.37	2.50	3.51	2.17	2.20	2.30	3.41	2.04	2.10	2.23
Total Operating Expenses	12.81	9.27	9.57	10.33	10.30	9.46	9.16	8.79	14.00	10.19	9.35	9.51	8.75	9.48	10.11	10.26	9.35	8.31	8.75	8.44
Operating Income	(1.37)	(1.97)	(0.75)	(3.13)	(1.84)	(1.69)	(1.03)	(1.87)	(6.18)	(1.87)	0.02	(1.53)	(2.28)	(0.29)	(1.85)	(1.29)	(4.35)	(1.56)	(1.44)	(0.32)
Interest Expense	0.11	0.11	0.11	0.09	0.22	0.14	0.13	0.12	0.18	0.11	0.19	0.19	0.18	0.15	0.14	0.12	0.03	0.02	0.03	0.02
Pretax Income	--	(1.94)	(0.73)	1.25	(1.96)	(1.53)	(1.09)	(1.89)	(6.28)	(1.06)	0.87	0.18	(2.41)	(0.42)	(1.36)	(1.40)	(4.38)	(1.58)	0.73	(0.34)
Tax Provision	0.02	0.01	0.01	0.00	(0.06)	0.01	0.01	0.01	0.02	0.01	0.01	0.01	0.05	0.01	0.01	0.01	0.01	0.01	0.01	0.01
Net Income	(1.41)	(1.94)	(0.74)	(3.29)	(1.90)	(1.54)	(1.09)	(1.95)	(6.29)	(1.05)	0.87	0.19	(2.44)	(0.41)	(1.34)	(1.39)	(3.85)	(1.06)	1.23	0.17
Basic EPS	(0.09)	(0.13)	(0.05)	(0.22)	(0.13)	(0.11)	(0.08)	(0.14)	(0.44)	--	--	--	(0.17)	(0.03)	(0.09)	(0.09)	(0.26)	(0.07)	0.08	0.01
Diluted EPS	(0.09)	(0.13)	(0.05)	(0.22)	(0.13)	(0.11)	(0.08)	(0.14)	(0.44)	--	--	--	(0.17)	(0.03)	(0.09)	(0.09)	(0.26)	(0.07)	0.08	0.01

Cash Flow Statement

(in millions USD)

Metric	Q4 2025	Q3 2025	Q2 2025	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022	Q2 2022	Q1 2022	Q4 2021	Q3 2021	Q2 2021	Q1 2021
Operating Cash Flow	0.00	0.19	4.74	0.39	1.90	0.48	(0.86)	(2.14)	1.04	1.24	5.24	(1.42)	3.64	2.64	2.33	(0.15)	1.96	(0.10)	2.70	1.79
Capital Expenditures	-0.00	0.02	0.07	0.00	0.00	0.02	0.01	0.04	0.05	0.05	0.07	0.11	(0.15)	0.09	0.14	0.03	0.01	0.06	0.02	0.02
Free Cash Flow*	0.00	0.16	4.67	0.39	1.90	0.46	(0.86)	(2.18)	0.99	1.18	5.16	(1.53)	3.79	2.54	2.19	(0.18)	1.95	(0.16)	2.68	1.77
Investing Cash Flow	(3.07)	(0.69)	(0.94)	(0.06)	(0.03)	0.19	(0.05)	(0.06)	0.26	(0.10)	(0.10)	(0.17)	(0.64)	0.68	(0.17)	(13.54)	(0.03)	(0.11)	(0.05)	(0.32)
Financing Cash Flow	(0.68)	(0.39)	(5.68)	(0.76)	(1.38)	(0.54)	(0.31)	2.42	(1.49)	(0.88)	(3.28)	(1.78)	(2.78)	(1.99)	(1.21)	3.92	(0.74)	0.38	(1.90)	(1.30)

* Derived from reported values